Eli Lilly and Eagle Pharma settle antitrust and infringement claims

US-based Eagle Pharmaceuticals has dropped its patent infringement and antitrust claims against Eli Lilly.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Eli Lilly can’t avoid royalties in insulin suit

21 October 2021 Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.

Americas

FDA warns of ‘grave’ knock-on effects from Eagle decision

29 May 2020 The US Food and Drug Administration has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.

Americas

Fed Circuit affirms generic maker’s win over Eagle

11 May 2020 The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Eli Lilly and Eagle Pharma settle antitrust and infringement claims

More on this story

Editor's picks

Editor's picks

More features